Literature DB >> 6374063

Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies.

R I von Hanwehr, F M Hofman, C R Taylor, M L Apuzzo.   

Abstract

Mononuclear cell infiltrates are found to varying degrees in 30% to 60% of primary human central nervous system (CNS) gliomas. To explore the immunological importance of this, six operative glial tumors, eight non-glial tumors, and three normal brain specimens were studied. Utilizing an immunoperoxidase method, the authors examined frozen sections for lymphoid infiltrates expressing suppressor/cytotoxic and helper phenotypes, as identified with the Leu-1,2,3 monoclonal antibodies. Four of six gliomas demonstrated lymphoid infiltrates: three tumors exhibited a predominant suppressor/cytotoxic cell phenotype and the fourth showed mixed staining of suppressor/cytotoxic and helper cell phenotypes. Varying degrees of lymphoid infiltration characterized four out of eight non-glial primary CNS tumors. Two cases exhibited a prevalence of suppressor/cytotoxic phenotype cells, while two cases demonstrated a more heterogeneous pattern of phenotype expression. Normal brain sections revealed little or no evidence of mononuclear infiltrates. The immunobiological significance of these findings is discussed in the context of tumor-host interaction within the CNS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6374063     DOI: 10.3171/jns.1984.60.6.1138

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  27 in total

1.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

2.  Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma.

Authors:  T Morioka; T Baba; K L Black; W J Streit
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Immunobiology of brain tumors.

Authors:  E Frank; N de Tribolet
Journal:  Neurosurg Rev       Date:  1986       Impact factor: 3.042

Review 4.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

5.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

6.  Immunocytochemical study of the cellular immune response in meningiomas.

Authors:  M L Rossi; F Cruz Sanchez; J T Hughes; M M Esiri; H B Coakham
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

7.  Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation.

Authors:  T Morimura; C Neuchrist; K Kitz; H Budka; O Scheiner; D Kraft; H Lassmann
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

8.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

9.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 10.  Immunology of gliomas.

Authors:  N de Tribolet
Journal:  Childs Nerv Syst       Date:  1989-04       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.